|Articles|July 1, 2002
Eye drops delay onset of glaucoma
Author(s)Lynda Charters
Bethesda, MD-Glaucoma management has entered a new era. Based on the results of the long-awaited Ocular Hypertension Treatment Study (OHTS), physicians now have clear guidelines for treating patients at high risk for developing glaucoma that may actually prevent the disease.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA grants IDE approval to EyeYon Medical for its US clinical study of EndoArt
2
Ocular Therapeutix accelerates NDA submission plans for AXPAXLI for wet AMD
3
First patient treated in ViaLase’s IDE trial
4
Formosa Pharmaceuticals and Rxilient sign licensing and commercialization agreement for APP13007
5











































.png)


